ADMA Biologics, Inc.
ADMA
$9.36
-$0.18-1.89%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.98% | -0.27% | 18.39% | 12.00% | 13.80% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.98% | -0.27% | 18.39% | 12.00% | 13.80% |
| Cost of Revenue | -30.39% | -37.17% | -7.14% | -2.63% | 10.09% |
| Gross Profit | 28.34% | 32.17% | 40.24% | 26.76% | 17.01% |
| SG&A Expenses | 18.82% | 9.62% | 0.18% | 17.71% | 33.14% |
| Depreciation & Amortization | 71.88% | 120.00% | 104.00% | 35.71% | -77.46% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -9.14% | -19.67% | -3.55% | 3.75% | 16.47% |
| Operating Income | 22.54% | 44.19% | 63.74% | 28.69% | 9.18% |
| Income Before Tax | 25.29% | 70.78% | 77.44% | 29.30% | 11.84% |
| Income Tax Expenses | 111.21% | 80.25% | 115.83% | 1,219.88% | 55.13% |
| Earnings from Continuing Operations | 10.53% | 68.48% | -55.87% | 1.45% | 6.73% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 10.53% | 68.48% | -55.87% | 1.45% | 6.73% |
| EBIT | 22.54% | 44.19% | 63.74% | 28.69% | 9.18% |
| EBITDA | 20.89% | 41.47% | 60.92% | 27.56% | 8.75% |
| EPS Basic | 16.94% | 69.76% | -56.16% | -0.26% | 2.76% |
| Normalized Basic EPS | 28.84% | 48.01% | 70.32% | 32.99% | 10.79% |
| EPS Diluted | 14.29% | 72.73% | -52.82% | 0.00% | 7.69% |
| Normalized Diluted EPS | 31.44% | 49.88% | 72.76% | 35.29% | 12.11% |
| Average Basic Shares Outstanding | -5.49% | -0.72% | 0.65% | 1.72% | 3.90% |
| Average Diluted Shares Outstanding | -7.35% | -1.93% | -0.83% | -0.06% | 2.66% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |